Dare Bioscience (NASDAQ:DARE) Posts Earnings Results, Beats Estimates By $0.10 EPS

Dare Bioscience (NASDAQ:DARE) announced its earnings results on Thursday. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.10, Zacks reports. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.00 million.

Here are the key takeaways from Dare Bioscience’s conference call:

• Commercialization has begun with Flora Sync LF5 launched in June and DARE to PLAY sildenafil cream expected to begin prescription dispensing in the third quarter, creating initial product revenue opportunities.
• Daré is building a multi-product commercial platform through its DARE Health Hub, provider relationships, telehealth partnerships, and digital marketing, with management targeting stronger, more efficient growth in 2027 and beyond.
• The pipeline advanced, including positive interim safety results for the pivotal Ovaprene contraceptive study, initiation of a phase II DARE-HPV trial, and an additional $1 million NIAID funding award that brings total DARE-HPV project funding to $2 million.
• Financial resources remain limited, with approximately $12.6 million in cash, a $0.2 million working-capital deficit, and only about $0.2 million in second-quarter revenue; Flora Sync sales were not reflected until July.
• Although the FDA approved an Ovaprene protocol amendment removing the requirement for 250 completers, it strongly recommended maintaining that target and indicated it may be necessary to adequately characterize safety, creating potential regulatory and timeline risk.

Dare Bioscience Stock Down 36.3%

DARE traded down $0.50 during trading on Friday, hitting $0.87. The company’s stock had a trading volume of 5,131,648 shares, compared to its average volume of 387,505. The firm has a market capitalization of $13.16 million, a P/E ratio of -0.91 and a beta of 1.08. Dare Bioscience has a twelve month low of $0.77 and a twelve month high of $3.78. The stock’s fifty day moving average price is $1.76 and its 200-day moving average price is $1.88.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DARE. Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Dare Bioscience to a “hold” rating in a research report on Saturday, May 23rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Trading of Dare Bioscience

Several hedge funds have recently modified their holdings of DARE. Virtu Financial LLC acquired a new position in shares of Dare Bioscience during the 3rd quarter valued at $37,000. Raymond James Financial Inc. grew its holdings in Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares during the period. Finally, LPL Financial LLC acquired a new stake in Dare Bioscience in the fourth quarter worth $28,000. Institutional investors own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.